Skip to main content

Advertisement

SpringerLink
Log in

Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Re-evaluation of the subtype of recurrent breast cancer is necessary for deciding the treatment approach, but it is often not performed due to the difficulty of obtaining tissue specimens from a recurrent lesion, etc. However, when a recurrent lesion is close to the body surface, fine-needle aspiration cells (FNA cells) can be easily obtained, and immunocytochemical (ICC) analysis of hormone receptors expression in FNA cells is said to be highly reliable. However, there is no consensus regarding ICC analysis of human epidermal growth factor receptor type 2 (HER2) expression and the Ki67 index using FNA cells.

Methods

Touch-smear cells (TSC) were prepared from resected specimens from 36 patients with primary invasive ductal carcinoma of the breast. The TSC were fixed in 95 % ethanol and subjected to ICC analysis for HER2 using HercepTest™ (Dako) and Ki67 using MIB-1™ (Dako). HER2 expression and the Ki67 index for the TSC were compared with the results of immunohistochemical analysis of histological section (HS). Statistical analyses used the kappa test and Pearson’s correlation coefficients.

Results

HER2 and Ki67 were analyzed in TSC from 36 and 28 patients, respectively. The HER2 expression scores in the TSC and HS groups showed good agreement (kappa value =0.640) and significant correlation (correlation coefficient =0.860, p < 0.001). The Ki67 indexes in the TSC and HS groups also showed significant correlation (correlation coefficient =0.861, p < 0.001).

Conclusions

The reliability of ICC analysis of HER2 expression and the Ki67 index using TSC were recognized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nishimura R, Aogi K, Yamamoto T, Takabatake D, Takashima S, Teramoto N, Kagawa A, Morita S. Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch. 2011;458:153–8.

    Article  CAS  PubMed  Google Scholar 

  2. Ferguson J, Chamberlain P, Cramer HM, Wu HHER. PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies. Diagn Cytopathol. 2013;41:575–81.

    Article  PubMed  Google Scholar 

  3. Ramljak V, Sučić M, Vrdoljak DV, Borojević N. Expression of Ki-67 and p27 (Kip1) in fine-needle aspirates from breast carcinoma and benign breast diseases. Diagn Cytopathol. 2011;39:333–40.

    Article  PubMed  Google Scholar 

  4. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. American Society of Clinical Oncology; College of American Pathologists Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.

    Article  PubMed  Google Scholar 

  5. Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep. 2007;13:17–25.

    Article  Google Scholar 

  6. Bédard YC, Pollett AF, Leung SW, O’Malley FP. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol. 2003;47:979–84.

    Article  PubMed  Google Scholar 

  7. Beatty BG, Bryant R, Wang W, Ashikaga T, Gibson PC, Leiman G, et al. HER-2/neu detection in fine-needle aspirates of breast cancer fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004;122:246–55.

    Article  CAS  PubMed  Google Scholar 

  8. Moriki T, Takahashi T, Ueta S, Mitani M. Ichien M. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004;30:251–6.

    Article  PubMed  Google Scholar 

  9. Sumiyoshi K, Shibayama Y, Akashi S, Nohara T, Iwamoto M, Kobayashi T, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? Oncol Rep. 2006;15:803–8.

    CAS  PubMed  Google Scholar 

  10. Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer. 2009;117:279–88.

    PubMed  Google Scholar 

  11. Williams SL, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations. Int J Clin Exp Pathol. 2009;2:476–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Kumar SK, Gupta N, Rajwanshi A, Joshi K, Singh G. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathology. 2012;23:181–6.

    Article  CAS  PubMed  Google Scholar 

  13. Pegolo E, Machin P, Riosa F, Bassini A, Deroma L, Loreto CD. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination. Cancer Cytopathol. 2012;120:196–205.

    Article  PubMed  Google Scholar 

  14. Corkill ME, Katz R. Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol. 1994;11:250–4.

    Article  CAS  PubMed  Google Scholar 

  15. Troncone G, Panico L, Vetrani A, de Divitiis B, Zeppa P, Fulciniti F, et al. c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol. 1996;14:135–9.

    Article  CAS  PubMed  Google Scholar 

  16. Solomides CC, Zimmerman R, Bibbo M. Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma. Anal Quant Cytol Histol. 1999;21:121–5.

    CAS  PubMed  Google Scholar 

  17. DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res. 2002;62:6667–73.

    CAS  PubMed  Google Scholar 

  18. Rita N, Cecilia B, Nadia N, Annamaria G, Marzio G, Maria M, et al. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer. 2000;90:61–6.

    Article  Google Scholar 

Download references

Conflict of interest

All authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan

    Masami Morimoto, Misako Nakagawa, Hirokazu Takechi, Takahiro Yoshida, Yukiko Tadokoro & Akira Tangoku

  2. Division of Pathology, Tokushima University Hospital, Tokushima, Japan

    Yoshimi Bando

  3. Higashi Tokushima Medical Center, Tokushima, Japan

    Junko Honda

  4. Department of Pathology, Kawasaki Medical School, Okayama, Japan

    Takuya Moriya

  5. Tokushima Breast Care Clinic, Tokushima, Japan

    Mitsunori Sasa

Authors
  1. Masami Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshimi Bando
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Misako Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirokazu Takechi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takahiro Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Junko Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yukiko Tadokoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takuya Moriya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mitsunori Sasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akira Tangoku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masami Morimoto.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morimoto, M., Bando, Y., Nakagawa, M. et al. Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable. Breast Cancer 23, 577–582 (2016). https://doi.org/10.1007/s12282-015-0605-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-015-0605-z

Keywords

Search

Navigation